Severe Chronic Cardiovascular Disease Focus

 Aastrom Biosciences
Description: Cardiovascular Disease, Autologus Stem cell Therapy, Late Phase 2 CLI Clinical development Program, cGMP quality Cell production system, Patient Safety Research Overview, Advantages of Aastrom Autologous Stem Cell Therapy, Targeting Niche Cardiovascular Disease Indications, High Unmet Medical Need, Restore CLI clinical Trial, CLI Interim Analysis, Dilated Cardiomyopathy DCM, Tissue Repair Cells Production and delivery, Future of Cardiovascular Disease Therapy
Views: 1721
Domain: Business
Category: Companies
Aastrom Biosciences
Focused on Severe Chronic Cardiovascular Diseases


Safe Harbor
This presentation contains forward-looking statements, including, without
limitation, statements concerning product-development objectives, clinical
trial strategies, clinical trial timing and expected results, market data,
potential market opportunities, market development plans, anticipated
milestones and pote ... See more

Recent Presentations

Positioning IMERYS for Profitable Growth

IMERYS strategy for profitable growth is focused on high-growth geographies, centralized purchasing, functional excellence, Simpler & delayered organization.

16 July, 2019
Jim Lico
15 July, 2019

BHP Strategy Briefing

BHP strategy is the best capabilities, commodities, assets to create long-term value & high returns. Transformation, capital discipline enable the successful execution of its strat

Peter Beaven
13 July, 2019